{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:53:03Z","timestamp":1790034783575,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1007\/s11926-001-0055-9","type":"journal-article","created":{"date-parts":[[2007,6,9]],"date-time":"2007-06-09T05:03:24Z","timestamp":1181365404000},"page":"86-91","source":"Crossref","is-referenced-by-count":31,"title":["COX-2 inhibitors in rheumatoid arthritis"],"prefix":"10.1007","volume":"3","author":[{"given":"John S.","family":"Sundy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"55_CR1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232\u2013235.","journal-title":"Nat New Biol"},{"key":"55_CR2","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","volume":"104","author":"JR Vane","year":"1998","unstructured":"Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:2S-8S.","journal-title":"Am J Med"},{"key":"55_CR3","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/S0021-9258(18)53294-4","volume":"268","author":"EA Meade","year":"1993","unstructured":"Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993, 268:6610\u20136614.","journal-title":"J Biol Chem"},{"key":"55_CR4","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","volume":"96","author":"TD Warner","year":"1999","unstructured":"Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999, 96:7563\u20137568.","journal-title":"Proc Natl Acad Sci USA"},{"key":"55_CR5","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI117620","volume":"94","author":"RC Harris","year":"1994","unstructured":"Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN and Breyer MD: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504\u20132510.","journal-title":"J Clin Invest"},{"key":"55_CR6","first-page":"F460","volume":"272","author":"M Komhoff","year":"1997","unstructured":"Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997, 272:F460-F468.","journal-title":"Am J Physiol"},{"key":"55_CR7","first-page":"349","volume-title":"Inflammation: Basic Principles and Clinical Correlates","author":"R Griffiths","year":"1999","unstructured":"Griffiths R: Prostaglandins and inflammation. In Inflammation: Basic Principles and Clinical Correlates, Edited by Gallin JI, Snydermans R. Philadelphia: Lippincott Williams & Wilkins; 1999:349\u2013360."},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0090-6980(99)00028-3","volume":"58","author":"T Hishinuma","year":"1999","unstructured":"Hishinuma T, Nakamura H, Sawai T, Uzuki M, Itabash Y, Mizugaki M: Microdetermination of prostaglandin E2 in joint fluid in rheumatoid arthritis patients using gas chromatography\/selected ion monitoring. Prostaglandins Other Lipid Mediat 1999, 58:179\u2013186.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"55_CR9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1172\/JCI115591","volume":"89","author":"H Sano","year":"1992","unstructured":"Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, Wilder RL: In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992, 89:97\u2013108.","journal-title":"J Clin Invest"},{"key":"55_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1172\/JCI117060","volume":"93","author":"LJ Crofford","year":"1994","unstructured":"Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994, 93:1095\u20131101.","journal-title":"J Clin Invest"},{"key":"55_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/03009749009092624","volume":"19","author":"E Seppala","year":"1990","unstructured":"Seppala E, Nissila M, Isomaki H, Wuorela H, Vapaatalo H: Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. Scand J Rheumatol 1990, 19:71\u201375.","journal-title":"Scand J Rheumatol"},{"key":"55_CR12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jama.1965.03080260021006","volume":"192","author":"K Fremont-Smith","year":"1965","unstructured":"Fremont-Smith K, Bayles T: Salicylate therapy in rheumatoid arthritis. JAMA 1965, 192:1133.","journal-title":"JAMA"},{"key":"55_CR13","first-page":"469","volume":"11","author":"AA Borg","year":"1993","unstructured":"Borg AA, Fowler PD, Shadforth MF, Dawes PT: Use of the Stoke Index to differentiate between disease-modifying agents and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Exp Rheumatol 1993, 11:469\u2013472.","journal-title":"Clin Exp Rheumatol"},{"key":"55_CR14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/03009749309095135","volume":"22","author":"PC Gotzsche","year":"1993","unstructured":"Gotzsche PC: Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. Scand J Rheumatol 1993, 22:255\u2013260.","journal-title":"Scand J Rheumatol"},{"key":"55_CR15","first-page":"1565","volume":"16","author":"ME Luggen","year":"1989","unstructured":"Luggen ME, Gartside PS, Hess EV: Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value. J Rheumatol 1989, 16:1565\u20131569.","journal-title":"J Rheumatol"},{"key":"55_CR16","first-page":"1874","volume":"19","author":"T Pincus","year":"1992","unstructured":"Pincus T, Marcum SB, Callahan LF, et al.: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol 1992, 19:1874\u20131884.","journal-title":"J Rheumatol"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/archinte.154.2.157","volume":"154","author":"PA Rochon","year":"1994","unstructured":"Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC: A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994, 154:157\u2013163.","journal-title":"Arch Intern Med"},{"key":"55_CR18","first-page":"184","volume":"18","author":"M Wijnands","year":"1991","unstructured":"Wijnands M, van Riel P, van \u2019t Hof M, Gribnau F, van de Putte L: Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study. J Rheumatol 1991, 18:184\u2013187.","journal-title":"J Rheumatol"},{"key":"55_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF00558371","volume":"19","author":"MN Dukes","year":"1981","unstructured":"Dukes MN, Lunde I: The regulatory control of non-steroidal anti-inflammatory agents. Eur J Clin Pharmacol 1981, 19:3\u201310.","journal-title":"Eur J Clin Pharmacol"},{"key":"55_CR20","first-page":"67","volume":"44","author":"T Pincus","year":"1993","unstructured":"Pincus T, Callahan LF: Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs. Agents Actions Suppl 1993, 44:67\u201375.","journal-title":"Agents Actions Suppl"},{"key":"55_CR21","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/bmj.1.6017.1048","volume":"1","author":"EC Huskisson","year":"1976","unstructured":"Huskisson EC, Woolf DL, Balme HW, Scott J, Franklin S: Four new anti-inflammatory drugs: responses and variations. Br Med J 1976, 1:1048\u20131049.","journal-title":"Br Med J"},{"key":"55_CR22","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","volume":"282","author":"LS Simon","year":"1999","unstructured":"Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999, 282:1921\u20131928.","journal-title":"JAMA"},{"key":"55_CR23","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","volume":"354","author":"P Emery","year":"1999","unstructured":"Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354:2106\u20132111.","journal-title":"Lancet"},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S0149-2918(99)80048-4","volume":"21","author":"TJ Schnitzer","year":"1999","unstructured":"Schnitzer TJ, Truitt K, Fleischmann R, et al.: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999, 21:1688\u20131702. 22-24. These trials represent the entire published data set that describes the efficacy of the selective COX-2 inhibitors in rheumatoid arthritis and present evidence that COX-2 inhibitors reduce the incidence of gastroduodenal ulcers detected by endoscopy.","journal-title":"Clin Ther"},{"key":"55_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/0002-9343(89)90344-6","volume":"86","author":"RT and Vender RJ Schoen","year":"1989","unstructured":"Schoen RT and Vender RJ: Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989, 86:449\u2013458.","journal-title":"Am J Med"},{"key":"55_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/art.1780360404","volume":"36","author":"SE Gabriel","year":"1993","unstructured":"Gabriel SE, Jaakkimainen RL, Bombardier C: The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993, 36:447\u2013459.","journal-title":"Arthritis Rheum"},{"issue":"Suppl:36","key":"55_CR27","first-page":"63","volume":"19","author":"MC Hochberg","year":"1992","unstructured":"Hochberg MC: Association of nonsteroidal antiinflammatory drugs with upper gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol 1992, 19(Suppl:36):63\u201367.","journal-title":"J Rheumatol"},{"key":"55_CR28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","volume":"115","author":"SE Gabriel","year":"1991","unstructured":"Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787\u2013796.","journal-title":"Ann Intern Med"},{"key":"55_CR29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-127-6-199709150-00003","volume":"127","author":"R Tamblyn","year":"1997","unstructured":"Tamblyn R, Berkson L, Dauphinee WD, et al.: Unnecessary prescribing of NSAIDs and the management of NSAIDrelated gastropathy in medical practice. Ann Intern Med 1997, 127:429\u2013438.","journal-title":"Ann Intern Med"},{"key":"55_CR30","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","volume":"340","author":"MM Wolfe","year":"1999","unstructured":"Wolfe MM, Lichtenstein DR and Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888\u201399. This is a comprehensive yet concise update on the pathogenesis, prevention and treatment of nonsteroidal antiinflammatory drug-induced gastrointestinal toxicity.","journal-title":"N Engl J Med"},{"key":"55_CR31","doi-asserted-by":"publisher","first-page":"31S","DOI":"10.1016\/S0002-9343(98)00072-2","volume":"105","author":"G Singh","year":"1998","unstructured":"Singh G: Recent considerations in nonsteroidal antiinflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.","journal-title":"Am J Med"},{"key":"55_CR32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(88)92892-9","volume":"2","author":"DY Graham","year":"1988","unstructured":"Graham DY, Agrawal NM, Roth SH: Prevention of NSAIDinduced gastric ulcer with misoprostol: multicentre, doubleblind, placebo-controlled trial. Lancet 1988, 2:1277\u20131280.","journal-title":"Lancet"},{"key":"55_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","volume":"123","author":"FE Silverstein","year":"1995","unstructured":"Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241\u2013249.","journal-title":"Ann Intern Med"},{"key":"55_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJM199803123381105","volume":"338","author":"CJ Hawkey","year":"1998","unstructured":"Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727\u2013734.","journal-title":"N Engl J Med"},{"key":"55_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM199803123381104","volume":"338","author":"ND Yeomans","year":"1998","unstructured":"Yeomans ND, Tulassay Z, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338:719\u2013726.","journal-title":"N Engl J Med"},{"key":"55_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/bmj.297.6655.1017","volume":"297","author":"RS Ehsanullah","year":"1988","unstructured":"Ehsanullah RS, Page MC, Tildesley G, Wood JR: Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988, 297:1017\u20131021.","journal-title":"BMJ"},{"key":"55_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/BF01536266","volume":"34","author":"MG Robinson","year":"1989","unstructured":"Robinson MG, Griffin JW Jr., et al.: Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989, 34:424\u2013428.","journal-title":"Dig Dis Sci"},{"key":"55_CR38","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","volume":"334","author":"AS Taha","year":"1996","unstructured":"Taha AS, Hudson N, Hawkey CJ, et al.: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996, 334:1435\u2013439.","journal-title":"N Engl J Med"},{"key":"55_CR39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-115-3-195","volume":"115","author":"NM Agrawal","year":"1991","unstructured":"Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, Stromatt SC: Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991, 115:195\u2013200.","journal-title":"Ann Intern Med"},{"key":"55_CR40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","volume":"43","author":"C Hawkey","year":"2000","unstructured":"Hawkey C, Laine L, Simon T, et al.: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebocontrolled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000, 43:370\u2013377. This study describes the reduction in endoscopically detected gastroduodenal ulcers in patients taking rofecoxib.","journal-title":"Arthritis Rheum"},{"key":"55_CR41","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"MJ Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ, et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929\u20131933. This study presents the first evidence that patients receiving cyclooxygenase-2 inhibitors have fewer clinically important gastroduodenal ulcers than those receiving traditional nonsteroidal antiinflammatory drugs.","journal-title":"JAMA"},{"key":"55_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0016-5085(99)70545-7","volume":"117","author":"B Cryer","year":"1999","unstructured":"Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999, 117:17\u201325.","journal-title":"Gastroenterology"},{"key":"55_CR43","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","volume":"106","author":"A Whelton","year":"1999","unstructured":"Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S.","journal-title":"Am J Med"},{"key":"55_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0009-9236(99)70056-1","volume":"66","author":"J Rossat","year":"1999","unstructured":"Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999, 66:76\u201384.","journal-title":"Clin Pharmacol Ther"},{"key":"55_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-133-1-200007040-00002","volume":"133","author":"SK Swan","year":"2000","unstructured":"Swan SK, Rudy DW, Lasseter KC, et al.: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000, 133:1\u20139.","journal-title":"Ann Intern Med"},{"key":"55_CR46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0272-6386(00)70266-6","volume":"35","author":"MA Perazella","year":"2000","unstructured":"Perazella MA, Eras J: Are selective COX-2 inhibitors nephrotoxic?\n                           Am J Kidney Dis 2000, 35:937\u2013940.","journal-title":"Am J Kidney Dis"},{"key":"55_CR47","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.1016\/S0002-9343(99)00114-X","volume":"106","author":"AI Schafer","year":"1999","unstructured":"Schafer AI: Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999, 106:25S-36S.","journal-title":"Am J Med"},{"key":"55_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/00912700022008766","volume":"40","author":"PT Leese","year":"2000","unstructured":"Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000, 40:124\u2013132.","journal-title":"J Clin Pharmacol"},{"key":"55_CR49","first-page":"2539","volume":"26","author":"A Karim","year":"1999","unstructured":"Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS: Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999, 26:2539\u20132543.","journal-title":"J Rheumatol"},{"key":"55_CR50","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/art.1780390503","volume":"39","author":"American College of Rheumatology Ad Hoc Committee on Clinical Guidelines","year":"1996","unstructured":"Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996, 39:723\u2013731.","journal-title":"Arthritis Rheum"},{"key":"55_CR51","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0149-2918(00)87238-0","volume":"21","author":"R Patterson","year":"1999","unstructured":"Patterson R, Bello AE and Lefkowith J: Immunologic tolerability profile of celecoxib. Clin Ther 1999, 21:2065\u20132079.","journal-title":"Clin Ther"},{"key":"55_CR52","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2","volume":"43","author":"F Wolfe","year":"2000","unstructured":"Wolfe F, Zhao S and Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000, 43:378\u2013385.","journal-title":"Arthritis Rheum"},{"key":"55_CR53","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.1780390502","volume":"39","author":"American College of Rheumatology Ad Hoc Committee on Clinical Guidelines","year":"1996","unstructured":"Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996, 39:713\u2013722.","journal-title":"Arthritis Rheum"},{"key":"55_CR54","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.282.20.1961","volume":"282","author":"WL Peterson","year":"1999","unstructured":"Peterson WL, Cryer B: COX-1-sparing NSAIDs--is the enthusiasm justified?. JAMA 1999, 282:1961\u20131963. This editorial provides a thoughtful approach to the competing concerns of minimizing nonsteroidal antiinflammatory druginduced gastrointestinal toxicity while managing the impact of medication costs.","journal-title":"JAMA"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-001-0055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-001-0055-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-001-0055-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-001-0055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T12:50:00Z","timestamp":1652619000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-001-0055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s11926-001-0055-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}